Keyphrases
Overactive Bladder Symptom Score (OABSS)
100%
Tolterodine
57%
Solifenacin
33%
Quality of Life Outcomes
33%
Symptom Bother
33%
Incontinence
25%
Extended Release
23%
Vesicare
22%
Open-label Trial
22%
Stress Urinary Incontinence
22%
Magnetic Resonance Imaging
22%
Abdominal Sacrocolpopexy
21%
Urinary Incontinence
21%
Pelvic Organ Prolapse Quantification (POP-Q)
20%
Once-daily
20%
Oxybutynin
17%
Health-related Quality of Life
16%
Paravaginal Repair
16%
Tension-free Vaginal Tape
16%
Surgical Treatment
16%
Patient Perception of Bladder Condition
16%
Tolerability
16%
Patient-reported Outcomes
14%
Antimuscarinics
14%
Pelvic Landmarks
13%
Placebo
13%
Nocturia
13%
Bladder Diary
12%
Visual Analog Scale
11%
Transabdominal Procedures
11%
Patient-reported Symptoms
11%
Support Person
11%
Clinical Efficacy
11%
Retropubic Urethropexy
11%
Cervical Stump
11%
Fesoterodine
11%
COVID-19
11%
Vaginal Prolapse Surgery
11%
First Week
11%
Pharmaceutics
11%
Mesh Erosion
11%
Apical Vaginal Prolapse
11%
Black Men
11%
Effectiveness Study
11%
Ureter
11%
Ischium
11%
Pelvic Floor Disorders
11%
Periosteum
11%
Bladder Injury
11%
Occult
11%
Medicine and Dentistry
Pelvic Organ Prolapse
42%
Sacrocolpopexy
30%
Stress Incontinence
25%
Pelvis
23%
Incontinence
23%
Quality of Life
22%
Magnetic Resonance Imaging
19%
Surgery
14%
Vaginal Wall
14%
Incision
13%
Health Care Cost
13%
Pelvic Magnetic Resonance Imaging
12%
Urine Incontinence
11%
Enuresis
11%
Pelvic Floor Dysfunction
11%
Periosteum
11%
Solifenacin
11%
Tension-Free Vaginal Tape Procedure
11%
Bariatric Surgery
11%
Patient Preference
11%
COVID-19
11%
Infection
11%
Ureter
11%
Bladder Injury
11%
Overactive Bladder
11%
Cohort Analysis
11%
Surgeon
9%
Urodynamics
9%
Pelvic Floor
8%
Bladder
7%
Urge Incontinence
6%
Coughing
6%
Nulliparous
6%
Hysterectomy
6%
Obturator Canal
5%
Cosmetics
5%
Bulking Agent
5%
Sphincter
5%
Uterine Prolapse
5%
Pubic Bone
5%
Laparoscopic Surgery
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Pharmacology, Toxicology and Pharmaceutical Science
Overactive Bladder
88%
Tolterodine
57%
Solifenacin
22%
Oxybutynin
17%
Tolerability
16%
Open-Label Trial
15%
Placebo
14%
Adverse Event
11%
Urge Incontinence
11%
Stress Incontinence
11%
Bladder Injury
11%
Fesoterodine
11%
Tuberculosis
11%
Xerostomia
10%
Nocturia
8%
Incontinence
7%
HIV
6%
Clinical Trial
6%
Cholinergic Receptor Blocking Agent
6%
Urinary Urgency
5%
Postmarketing Surveillance
5%
